

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

TITLE: Patient Preference Between the ProSomnus IA and TAP 3 Mandibular Advancement Devices in Patients Who Brux

Andrew S. Ryser, DDS, ^a Jennifer Sabol, DDS, ^b Steven Handel, DMD, ^c Patricia Walworth, DMD, ^d Walter Dimalanta, DMD, ^e Sloan McLaughlin, DMD, ^f Maddie E. Ryser, DNP, FNP-BC, ^g Kyung Kim, DMD, ^h

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

^a Prosthodontic Resident, CPT, Department of Prosthodontics, Army Postgraduate Dental School, Postgraduate Dental College, Uniformed Services University, Fort Eisenhower, GA, USA

^b Program Director, COL, Department of Prosthodontics, Army Postgraduate Dental School, Postgraduate Dental College, Uniformed Services University, Fort Eisenhower, GA, USA

^c Assistant Program Director, LTC, Department of Prosthodontics, Army Postgraduate Dental School, Postgraduate Dental College, Uniformed Services University, Fort Eisenhower, GA, USA

^d Prosthodontist, MAJ, US Army, Fort Sam Houston, Texas

^e Prosthodontist, COL, US Army, Fort Bliss, Texas

21 ^f Assistant Program Director, LTC, Department of Prosthodontics, Army Postgraduate Dental
22 School, Postgraduate Dental College, Uniformed Services University, Fort Eisenhower, GA,
23 USA

24 ^g Private Practice, Georgia

25 ^h Assistant Program Director, COL, Department of Prosthodontics, Army Postgraduate Dental
26 School, Postgraduate Dental College, Uniformed Services University, Fort Eisenhower, GA,
27 USA

28 **Corresponding Author:**

29 Andrew Ryser

30 606 Bunchgrass St, Evans, GA

31 Phone: 330-719-5003

32 Email: ryser.3@osu.edu

33

34 Details of Clinical Report:

35 From: Naval Medical Center Portsmouth IRB Office

36 IRB Number: DDEAMC.2022.0052

37 Study Title: Patient Preference between the ProSomnus IA and ADL Tap 3 Mandibular
38 Advancement Devices in Patients Who Brux

39 Submission Form EIRB Reference: 947705

40 IRB Approval Date: 05/18/2022

41 **DISCLAIMER**

42 The views expressed in this manuscript are those of the authors and do not necessarily reflect the
43 official policy of the United States Government, the Department of Defense, the Defense Health
44 Agency, or Uniformed Services University.

45 **FINANCIAL DISCLOSURE:** none

46

47 **ABSTRACT**

48 **Study Objectives:**

49 This qualitative analysis compared patient preference between a modified ProSomnus IA
50 and TAP 3 appliances in patients diagnosed with obstructive sleep apnea (OSA) and bruxism.

51 **Methods:**

52 A ProSomnus IA modified with the wings extended laterally 2 mm and a TAP 3 MAD
53 were prescribed to 13 patients with bruxism and OSA. One MAD was delivered and used for one
54 month. After one month the patient returned to the clinic and received the second MAD. At the
55 final appointment the patient was asked which device was preferred for long-term treatment.

56 **Results:**

57 Eight of 13 patients enrolled in this study preferred the ProSomnus IA for treatment of
58 OSA over the TAP 3. One patient was not able to tolerate either device and two dropped out of
59 the study. The two patients who preferred the TAP 3 also used a CPAP simultaneously.

60 **Conclusion:**

61 The modified ProSomnus IA was the preferred device for patients with OSA and bruxism.
62 Patients who used the CPAP and a MAD preferred the TAP 3 initially however those two patients
63 later switched back to the ProSomnus IA due to issues with their TAP 3.

64 **Practical Implications:**

65 Choosing the preferred device first will allow the patient to potentially receive successful
66 treatment for OSA and bruxism in a timelier manner, increasing compliance, saving valuable
67 clinic time and preventing costly remakes.

68

69 **KEYWORDS:**

70 Obstructive sleep apnea, mandibular advancement device, bruxism, sleep medicine

71

72 **INTRODUCTION**

73

74 Obstructive sleep apnea (OSA) is a major systemic health condition that is associated
75 with other medical comorbidities such as stroke, hypertension, diabetes, cognitive functions,
76 depression, and excessive daytime sleepiness.¹ It is estimated that 3-7% of men and 2-5% of
77 women have obstructive sleep apnea.² OSA risk increases with age and is more common in men.
78 It is estimated that 80-90% of those with obstructive sleep apnea remain undiagnosed.² OSA and
79 its associated comorbidities decrease readiness of the individual Soldier and the overall readiness
80 of the military. According to a 2022 study by Haynes et al, the prevalence of OSA among
81 military members is highest within the Army at 12.15%, followed by the Air Force at 9.96%, and
82 then the Navy with 9.06%.³ According to a study by Moore et al. in 2021, between 2005 and
83 2019, OSA incidence in the US military increased dramatically from 11 per 10,000 to 333 per

84 10,000, an increase of over 2900% Service members in the US Army tend to be diagnosed with
85 OSA at higher rates than the US Air Force and Navy.⁴

86 The gold standard for treatment of obstructive sleep apnea is continuous positive airway
87 pressure (CPAP), however several issues are of particular importance concerning the use of
88 CPAP in the military.⁵ First, CPAP usage has poor compliance with less than 50% of users
89 reporting compliance, defined as at least 4 hours per night for at least 5 nights a week of using
90 CPAP.⁵ Secondly, CPAP requires an electrical source, or at least a battery, to function, which is
91 not ideal for a field environment, such as training exercises, deployment to a war zone, or
92 humanitarian missions in rustic regions. Due to the poor compliance and intolerance by some
93 patients, and challenges with CPAP in certain situations such as austere conditions, the flexible
94 usage of mandibular advancement devices (MADs) have emerged as a viable alternative
95 treatment option.⁶

96 Mandibular advancement devices come in a variety of designs and can be classified as
97 prefabricated or customized. Customized MADs can be adjustable or nonadjustable.⁷ MADs can
98 be further classified according to their coupling mechanism of being attached or unattached.
99 Attached devices include midline traction, bilateral traction (bilateral pull), and bilateral
100 compression (bilateral push) MADs.⁷ Unattached devices include interlocking devices. Each type
101 of device has specific indications, advantages, and disadvantage that clinicians need to consider
102 when choosing the most appropriate design for each patient.⁷ The following factors will help
103 determine what MAD should be selected for specific patients: size of mouth, shape of arch,
104 existence of parafunctional habits such as bruxism, defective/vulnerable restorations and teeth,
105 vertical dimension concerns such as a deep bite, retentive elements of the dentition, the need for
106 an anterior airway, patient dexterity, the ability to titrate, and ease of titration for the patient.^{8,9,10}

107 When a patient presents with parafunctional habits such as nocturnal bruxism the device design
108 is critical to allow for lateral movement of the mandible.^{8,9,10}

109 As a large organization, the US Army spends a significant amount of money on treatment
110 of obstructive sleep apnea.¹¹ The US Army Dental Laboratory (Fort Eisenhower, Georgia, USA)
111 sent out 2,221 mandibular advancement devices in the fiscal year of 2022 totaling over six
112 million dollars in patient treatment received.¹¹ The Army currently uses five different MADs for
113 treatment of OSA. These include the ADL fabricated TAP 3, the DreamTAP, the ProSomnus IA,
114 Evo, and Herbst appliances (Pleasanton, California, USA). The TAP 3 allows for some lateral
115 movement and the ProSomnus IA must be modified to allow lateral movement. Lateral
116 movement of the device is important in patients who brux. A comparison of the TAP 3 and
117 ProSomnus IA device with modified wings will provide the military, medical, and dental
118 community an opportunity to see if one of these two devices is preferred in OSA patients who
119 brux. If a preference is determined, dental providers could use the preferred device to initiate
120 treatment of patients with OSA who also brux. Furthermore, the dental provider will have
121 increased confidence that they are choosing a device that will most likely be preferred, thus
122 avoiding costly remakes, not only in terms of finances and lost lab/clinical time but also avoiding
123 lost time for the provider and Soldier. Providing a MAD, the patient prefers will increase
124 compliance, decrease the comorbidities associated with OSA, and may decrease accident,
125 injuries, or even deaths caused by the effects of OSA. In the military, increasing effective
126 treatment of OSA will improve readiness and improve the service members' ability to complete
127 the mission.

128

129 **METHODS**

130 This qualitative analysis underwent an institutional review board and all participants
131 provided informed consent to participate in the study. A G Power analysis was completed to
132 estimate sample size, and was determined to be 10, with a significance criterion of .05 and a
133 power of .80. There was one main objective for this study: to see if there was a preference
134 between a modified ProSomnus IA and TAP 3 mandibular advancement devices in patients who
135 have OSA and brux. The ProSomnus IA was modified to have the wings extended laterally 2mm
136 to give the patient the ability for lateral movements of the mandible, as the TAP 3 also allows for
137 such movement.

138 Patients were referred to a prosthodontics clinic for treatment of OSA with mandibular
139 advancement devices, were then screened for bruxism by 1 or a combination of the following 3
140 methods: signs of bruxism based on an intraoral exam, patients stated his/her bed partner says
141 he/she grinds teeth while sleeping, or confirmation of bruxism on the polysomnogram (PSG). Once
142 screened and bruxism was confirmed, the patient was treated for OSA by receiving the following
143 two devices: the TAP 3 or the ProSomnus IA MAD with wings modified to extend laterally 2mm.
144 Digital impressions utilizing the CEREC Primescan (Dentsply Sirona, Charlotte, North Carolina,
145 USA) were made of the maxillary and mandibular arches as well as the protrusive position
146 determined by use of a George Gauge (Great Lakes Dental Technologies, Buffalo, New York,
147 USA) and vinyl polysiloxane bite registration material. Scanned standard tessellation language
148 (STL) files were sent to the lab for fabrication of the two devices.

149 In order to randomly select who received which device, a die was rolled and patients with
150 odd numbers received the TAP 3 appliance first and those that rolled even numbers received the
151 ProSomnus appliance first (randomization was done to account for potential recency and primacy
152 bias). Once the first device was delivered, adjustments were made to ensure it fit correctly and was

153 comfortable for the patient. After all adjustments were made, the patient used the first device for
154 at least one month and then returned to the clinic. Titrations to the protrusive position of the device
155 were made as needed based on subjective symptoms of the patient's quality of sleep. After a month,
156 the second device was delivered to the patient, adjusting for clinical acceptance and comfort and
157 was titrated as necessary. After at least one month of using the second device the patient returned
158 to the clinic.

159 At the final appointment, the patient was asked what device he or she preferred and would
160 like to go home with for long term treatment. Whichever device the patient preferred was the
161 device the patient was advised to use for treatment of OSA. The patients then were referred back
162 to sleep medicine or their primary care physician for follow up care and an efficacy PSG.

163 **STUDY RESULTS**

164 In total 13 patients were enrolled in the study and 13 patients received care under the
165 study. Eleven patients completed the study. One patient dropped out after receiving the
166 ProSomnus IA due to being transferred overseas and not being able to return to the clinic before
167 moving. A second patient dropped out of the study after receiving the IA and using it for a week .
168 Eight of the patients preferred the ProSomnus IA with the wings modified to extend laterally
169 2mm over the TAP 3 appliance. One patient could not tolerate the TAP 3 nor ProSomnus IA and
170 was given a ProSomnus Evo appliance for treatment of OSA. Two patients chose the TAP 3
171 appliance to treat their obstructive sleep apnea.

172 The following were reasons provided by the patients as to why they chose the ProSomnus
173 IA appliance or why they did not choose the TAP 3:

- 174 • The material of the IA was smoother and felt sturdier.

- 175 • The IA was more comfortable.
- 176 • The IA allowed the patient to move their jaw side to side.
- 177 • The IA felt like it would last a while.
- 178 • The IA did not prevent the patient from opening their mouth during sleep.
- 179 • The TAP 3 was hard to connect and the IA was easier to place in the mouth.

180 The following were reasons provided by the patients as to why they chose the TAP 3
181 appliance or why they did not choose the IA:

- 182 • Wearing the IA with a CPAP caused discomfort on the cheeks from the mask
183 pushing against the wings.

184 The following were reasons provided by the patients on why they chose to go back to the
185 ProSomnus IA after the research after they initially chose the TAP 3:

- 186 • The metal on the TAP 3 began to corrode.
- 187 • The screw kept loosening and the patient would lose the protrusive position.
- 188 • Patient would like to not use CPAP anymore and only use the MAD.

189 One patient dropped out of the study after receiving the ProSomnus IA MAD. The patient
190 called the clinic and stated he no longer wanted to participate in the study. The patient was given
191 the opportunity to come into to the clinic for an evaluation and to correct any issues related to the
192 MAD, however the patient refused to continue treatment. The same patient also was non-
193 compliant with CPAP after utilizing a full-face mask and a nasal mask. That patient was referred
194 back to the sleep clinic for long term care.

195

196 **DISCUSSION**

197 While CPAP is accepted as the standard treatment for obstructive sleep apnea,
198 compliance remains an issue for continuous long-term management. Compliance for the use of
199 CPAP is considered 4 hours per night for 70% of nights for 30 consecutive days.⁵ Patel et al.
200 reported CPAP adherence is between 17-71%, while Rotenberg, Muraiu and Pang noted an
201 average non-adherence rate of 34.1%.^{12,13} Surgical intervention for sleep apnea may be suitable
202 for some patients but this option is best for those with intolerances to CPAP or MAD,
203 anatomical abnormalities resulting in a narrowed airway, and/or facial features that impair an
204 appropriate mask fit.¹⁴ Mandibular advancement devices have greater compliance than CPAP
205 and have less risk than surgical interventions, however, the efficacy of treatment for MADs is
206 lower in patients with severe sleep apnea (AHI >30).^{15,16}

207 Bruxism is a condition in which a person grinds their teeth and can occur whether the
208 person is awake or asleep (nocturnal bruxism). The Glossary of Prosthodontic Terms defines
209 bruxism as “the parafunctional grinding of teeth; an oral habit consisting of involuntary rhythmic
210 or spasmodic nonfunctional gnashing, grinding, or clenching of teeth in other than chewing
211 movements of the mandible which may lead to occlusal trauma.”¹⁷ Bruxism is caused by a
212 variety of factors to include stress, depression, genetics, medications.^{18,19} If bruxism is mild, the
213 patient may not require treatment and symptoms may not be present. However, if the bruxism is
214 severe or causes obvious signs or symptoms, treatment may be warranted. Bruxism can cause
215 accelerated attrition of teeth leading to pain or sensitivity and might require restoration of the
216 teeth.²⁰ It can also cause TMD symptoms, myofascial pain, and headaches.²¹ Unfortunately,
217 treatment of bruxism often occurs once attrition of the teeth becomes severe or symptoms
218 become intolerable for the patient. Other treatment options include orthotic devices to prevent
219 wear of the dentition, behavioral management to reduce stress and depression, relaxation

220 techniques, limiting the use of caffeine, medications, and Botox.²² When a patient presents with
221 obstructive sleep apnea and bruxism, dentists can treat OSA and bruxism simultaneously,
222 preventing further damage from bruxism.²³ By allowing for lateral movement when selecting
223 which MAD to use, there may be improved compliance of wearing the prosthesis for a patient
224 diagnosed with OSA and bruxism. The additional benefit of being able to use a prosthesis in any
225 kind of environment regardless of power source gives MAD the flexibility that travelers require
226 without the inconvenience of a CPAP machine.

227 The majority of patients included in this study preferred the modified ProSomnus IA with
228 wings extended laterally 2 mm over the TAP 3 MAD. Patients provided many reasons for why
229 they chose the ProSomnus IA, while those who chose the TAP 3 did so due to simultaneous use
230 of a CPAP. The reasons for choosing the TAP 3 while also using CPAP was that the wings on
231 the IA would irritate the buccal mucosa because of pressure from the CPAP face mask. Patients
232 who did choose the TAP 3 preferred the ProSomnus IA over the TAP 3 if the CPAP was also not
233 utilized at night. Use of a CPAP plays a critical role in what MAD the dentist chooses to treat
234 OSA. If the wrong appliance is chosen, patient comfort and thus compliance can be affected.
235 Other factors such as nocturnal bruxism also must be taken into consideration to choose the
236 correct MAD design.

237 The manufacturing process and material of the MAD appeared to play a role in the
238 preference of the MAD. The ProSomnus IA is a milled PMMA interlocking mandibular
239 advancement device. The TAP 3 is an anterior midline traction device that is made from a
240 prefabricated bilaminar resin that utilizes suction and heat for fabrication on stone or printed
241 models. The ProSomnus is delivered to the patient smooth and glossy with a flat occlusal plane.
242 The TAP 3 is delivered to the patient and the occlusion is finalized by adding clear acrylic to the

243 occlusal portion of the mandibular device in order to achieve a tripod effect instead of all
244 occlusal force being placed at the anterior hook. When considering which MAD to prescribe to a
245 patient, a demonstration of the available MADs with a discussion on the material, mechanism of
246 action, and ability to titrate is crucial to allow the patient and clinician to choose the appropriate
247 MAD.

248 The TAP 3 showed significant concerns unrelated to the research including the loosening
249 of the anterior midline traction screw and corrosion of the metal pieces on the TAP 3. The TAP 3
250 also exhibited increased esthetic concerns because of discoloration of the bilaminate material
251 after a few months, when the ProSomnus IA maintained an esthetically pleasing look. Patients
252 stated their dissatisfaction with the need to add a different material to fill the interocclusal space
253 to achieve a tripod on the TAP 3, due to poor esthetics, and the concern that over time that
254 material would delaminate from the TAP 3 appliance.

255 Adjustments made to the IA appliance included reducing the extension of the borders and
256 minor occlusal adjustments. Alterations to the TAP 3 were more common and include
257 adjustments to the borders, adjustments to the intaglio to get complete seating of the device, and
258 addition of acrylic to form a tripod after the final titration position was located. The TAP 3 also
259 required adjustments to prevent the screw from loosening in the patients who used the MAD in
260 combination with a CPAP.

261 Although this study indicated a patient preference when treating OSA and bruxism with a
262 mandibular advancement device, only two types of appliances were tested. The ProSomnus IA
263 and TAP 3 MAD may not be the preferred devices used in all dental practices and were chosen
264 due to limitations of what MAD is available in the US Army. Further research is needed to test
265 all types of MADs in bruxers. Modification of the ProSomnus IA to extend wings laterally is a

266 factor the clinician should consider and request in the prescription to the company. Without
267 doing so, the ProSomnus IA would not allow for any lateral movement in bruxers. ProSomnus
268 has also introduced a newer version of the IA called the EVO and further studies using that
269 appliance should be completed to determine if there is a preference towards the unattached
270 bilateral push MAD is persistent in patients with OSA and bruxism. The TAP 3 appliance
271 appeared to have manufacturing defects in this study with corrosion and the screw loosening in
272 the anterior midline traction device. However, with a small sample size, conclusions cannot be
273 made, and further research is needed to examine this concern. More research is also needed to
274 determine how much lateral movement is preferred in MADs for patients who brux.

275

276 **CONCLUSION**

277 In this research the majority of patients, who required a mandibular advancement device
278 for treatment of OSA and bruxism, preferred the ProSomnus IA with wings modified laterally 2
279 mm over the TAP 3 MAD. When CPAP was also used, the patient preferred the TAP 3 MAD.
280 Patients who have OSA and brux appear to prefer a bilateral push milled appliance such as the
281 ProSomnus IA over a midline anterior traction MAD like the TAP 3. When utilizing a bilateral
282 push appliance like the ProSomnus IA, it might be important to modify the design of the MAD to
283 allow for lateral movements. If the patient utilizes a CPAP and MAD simultaneously, choosing a
284 MAD that would decrease irritation of the buccal mucosa is advisable. Other changes such as
285 type of mask and mode of delivery from CPAP might be indicated.

286

287 **PRACTICAL IMPLICATIONS**

288 This project compared the preference between the Prosomnus IA and TAP3 appliance in patients
289 that are diagnosed with obstructive sleep apnea and bruxism, potentially improving the decision
290 making for clinicians when treating a patient with OSA and bruxism. Choosing the preferred
291 device first will allow the patient to potentially receive successful treatment for OSA and
292 bruxism in a timelier manner, increasing compliance, saving valuable clinic time, and preventing
293 costly remakes. Although every practice might not use the two devices looked at in this study,
294 clinicians can apply what was learned to their practice and the appliances they prescribe.

295

296 REFERENCES

- 297 1. Pinto J, Cavallini A, Duarte C, Freitas G, Ribeiro D. Comorbidities associated with
298 obstructive sleep apnea: A retrospective study. *International Archives of*
299 *Otorhinolaryngology*. 2016;20:145-150. doi:10.1055/s-0036-1579546.
- 300 2. Park JG, Ramar K, Olson EJ. Updates on definition, consequences, and management of
301 obstructive sleep apnea. *Mayo Clin Proc*. 2011;86:549-54.
- 302 3. Haynes ZA, Stewart IJ, Poltavskiy EA, et al. Obstructive sleep apnea among survivors of
303 combat-related traumatic injury: a retrospective cohort study. *J Clin Sleep Med*.
304 2022;18:171–179.
- 305 4. Moore BA, Tison LM, Palacios JG, Peterson AL, Mysliwiec V. Incidence of insomnia and
306 obstructive sleep apnea in active duty United States military service members. *Sleep*.
307 2021;44:zsab024.
- 308 5. Qiao M, Xie Y, Wolff A, Kwon J. Long term adherence to continuous positive Airway
309 pressure in mild obstructive sleep apnea. *BMC Pulm Med*. 2023;23:320.

- 310 6. White DP, Shafazand S. Mandibular advancement device vs. CPAP in the treatment of
311 obstructive sleep apnea: are they equally effective in short term health outcomes? *J Clin*
312 *Sleep Med.* 2013;9:971-2.
- 313 7. Manetta IP, Ettlin D, Sanz PM, Rocha I, Meira E Cruz M. Mandibular advancement devices
314 in obstructive sleep apnea: an updated review. *Sleep Sci.* 2022;15:398-405.
- 315 8. Scherr S, Dort LC, Almeida FR, et al. Definition of an Effective Oral Appliance for the
316 Treatment of Obstructive Sleep Apnea and Snoring: A Report of the American Academy of
317 Dental Sleep Medicine. *Journal of Dental Sleep Medicine.* 2014;1:39-50.
- 318 9. Mogell K, Blumenstock N, Mason E, Rohatgi R, Shah S, Schwartz D. Definition of an
319 Effective Oral Appliance for the Treatment of Obstructive Sleep Apnea and Snoring: An
320 Update for 2019. *J Dent Sleep Med.* 2019;6:39-50.
- 321 10. Mayoral P, Lagravère MO, Míguez-Contreras M, Garcia M. Antero-posterior mandibular
322 position at different vertical levels for mandibular advancing device design. *BMC Oral*
323 *Health.* 2019;19:85.
- 324 11. Army Dental Laboratory Report FY 22
- 325 12. Patel SR, Bakker JP, Stitt CJ, Aloia MS, Nouraiie SM. Age and Sex Disparities in Adherence
326 to CPAP. *Chest.* 2021;159:382-389.
- 327 13. Rotenberg BW, Murariu D, Pang KP. Trends in CPAP adherence over twenty years of data
328 collection: a flattened curve. *J Otolaryngol Head Neck Surg.* 2016;45(1):43.
- 329 14. Mehra P, Wolford LM. Surgical management of obstructive sleep apnea. *Proc (Bayl Univ*
330 *Med Cent).* 2000;13:338-42.
- 331 15. Durán-Cantolla J, Crovetto-Martínez R, Alkhraisat MH, Crovetto M, Municio A, Kutz R,
332 Aizpuru F, Miranda E, Anitua E. Efficacy of mandibular advancement device in the treatment

- 333 of obstructive sleep apnea syndrome: A randomized controlled crossover clinical trial. Med
334 Oral Patol Oral Cir Bucal. 2015;20:e605-15.
- 335 **16.** Venema JAMU, Rosenmöller BRAM, de Vries N, de Lange J, Aarab G, Lobbezoo F, et al.
336 Mandibular advancement device design: A systematic review on outcomes in obstructive
337 sleep apnea treatment. *Sleep Medicine Reviews*. 2021;60:101557.
- 338 **17.** Prosthodontics, T. A. (2016). *Glossary of Prosthodontic Terms*. Retrieved from The Journal of
339 Prosthetic Dentistry: [https://www.thejpd.org/article/S0022-3913\(16\)30683-7/fulltext#secsectitle0010](https://www.thejpd.org/article/S0022-3913(16)30683-7/fulltext#secsectitle0010)
- 340 **18.** Shetty, S., Pitti, V., Satish Babu, C. L., Surendra Kumar, G. P., & Deepthi, B. C. (2010).
341 Bruxism: a literature review. *Journal of Indian Prosthodontic Society*, 2010;10:141–148.
- 342 **19.** Molina, O. F., & dos Santos, J., Jr Hostility in TMD/bruxism patients and controls: a clinical
343 comparison study and preliminary results. *Cranio : the journal of craniomandibular practice*,
344 2002;20:282–288.
- 345 **20.** Kanathila, H., Pangi, A., Poojary, B., & Doddamani, M. (2018). Diagnosis and treatment of
346 bruxism: Concepts from past to present. *International Journal of Applied Dental Sciences*,
347 290–295.
- 348 **21.** Ohlmann B, Waldecker M, Leckel M, Bömicke W, Behnisch R, Rammelsberg P, Schmitter
349 M. Correlations between Sleep Bruxism and Temporomandibular Disorders. *Journal of*
350 *Clinical Medicine*. 2020; 9:611.
- 351 **22.** Hajime Minakuchi, Masanori Fujisawa, Yuka Abe, Takashi Iida, Kyosuke Oki, Kazuo
352 Okura, Norimasa Tanabe, Akira Nishiyama, Managements of sleep bruxism in adult: A
353 systematic review, *Japanese Dental Science Review*, 2022;58:124-136.
- 354 **23.** Landary ML, et al. Reduction of sleep bruxism using a mandibular advancement device: an
355 experimental controlled study. *Int J Prosthodont*. 2006;19:549–556.
- 356